DelveInsight’s, “Atopic Dermatitis Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Atopic Dermatitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Atopic Dermatitis Pipeline Outlook

 

Key Takeaways from the Atopic Dermatitis Pipeline Report

• In September 2024:- Aclaris Therapeutics Inc.- A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants With Moderate to Severe Atopic Dermatitis.
• In September 2024:- Incyte Corporation- This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
• DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
• The leading Atopic Dermatitis Companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
• Promising Atopic Dermatitis Therapies such as Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.

 

Stay ahead with the most recent pipeline outlook for Atopic Dermatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Atopic Dermatitis Treatment Drugs

 

Atopic Dermatitis Emerging Drugs Profile

• Tapinarof: Dermavant Sciences

Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.

• Etrasimod: Pfizer

Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopic dermatitis.

• B244: AOBiome

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Atopic dermatitis.

• Lirentelimab: Allakos Inc.

Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody which activates the inhibitory receptor Siglec-8. Additionally, Lirentelimab depletes eosinophils via antibody dependent cellular cytotoxicity (ADCC) in blood. Siglec-8 is a member of the family of cell surface receptors called Sialic acid-binding immunoglobulin-type lectins (Siglecs). Allakos initiated a Phase II trial evaluating subcutaneous Lirentelimab versus placebo in patients with atopic dermatitis. Results from this trial are expected in the second half of 2023.

• QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. QY201 is an innovative drug for the treatment of atopic dermatitis. QY201 was independently developed by E-nitiate with global patents, is undergoing Phase I/II clinical trial for atopic dermatitis.

 

Explore groundbreaking therapies and clinical trials in the Atopic Dermatitis Pipeline. Access DelveInsight’s detailed report now! @ New Atopic Dermatitis Drugs

 

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Atopic Dermatitis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Unveil the future of Atopic Dermatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Atopic Dermatitis Market Drivers and Barriers

 

Scope of the Atopic Dermatitis Pipeline Report

• Coverage- Global
• Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
• Atopic Dermatitis Therapies- Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.
• Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Atopic Dermatitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Atopic Dermatitis Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Atopic Dermatitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Atopic Dermatitis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tapinarof: Dermavant Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. B244: AOBiome
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EP262: Escient Pharmaceuticals
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Atopic Dermatitis Key Companies
21. Atopic Dermatitis Key Products
22. Atopic Dermatitis- Unmet Needs
23. Atopic Dermatitis- Market Drivers and Barriers
24. Atopic Dermatitis- Future Perspectives and Conclusion
25. Atopic Dermatitis Analyst Views
26. Atopic Dermatitis Key Companies
27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/